Bacitracin, Neomyxin & Polymyxin B
14 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
14
Total Reports
2
Deaths Reported
1430.0%
Death Rate
Active Ingredients
Bacitracin, Neomyxin & Polymyxin B
Administration Routes
TopicalOphthalmic
Species Affected
Dog 7
Cat 6
Camel 1
Most Affected Breeds
Domestic Shorthair 6
Shepherd Dog - Anatolian 1
Terrier - Yorkshire 1
Retriever - Golden 1
Pekingese 1
Unknown 1
Terrier - Boston 1
Shih Tzu 1
Poodle - Toy 1
Most Reported Reactions
Lethargy (see also Central nervous system depression in 'Neurological') 7
Anorexia 5
Other abnormal test result NOS 3
Heart murmur 3
Injection site lump 3
Anaemia NOS 3
Application site alopecia 3
Eye redness 2
Death by euthanasia 2
Application site erythema 2
Skin lesion NOS 2
Erythema (for urticaria see Immune SOC) 2
Outcome Breakdown
Ongoing
7 (50.0%)
Outcome Unknown
3 (21.4%)
Euthanized
2 (14.3%)
Recovered/Normal
2 (14.3%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.